Literature DB >> 31049553

Sphingosine 1-phosphate and inflammation.

Hideru Obinata1, Timothy Hla2.   

Abstract

AbstractSphingosine 1-phosphate (S1P), a sphingolipid mediator, regulates various cellular functions via high-affinity G protein-coupled receptors, S1P1-5. The S1P-S1P receptor signaling system plays important roles in lymphocyte trafficking and maintenance of vascular integrity, thus contributing to the regulation of complex inflammatory processes. S1P is enriched in blood and lymph while maintained low in intracellular or interstitial fluids, creating a steep S1P gradient that is utilized to facilitate efficient egress of lymphocytes from lymphoid organs. Blockage of the S1P-S1P receptor signaling system results in a marked decrease in circulating lymphocytes because of a failure of lymphocyte egress from lymphoid organs. This provides a basis of immunomodulatory drugs targeting S1P1 receptor such as FTY720, an immunosuppressive drug approved in 2010 as the first oral treatment for relapsing-remitting multiple sclerosis. The S1P-S1P receptor signaling system also plays important roles in maintenance of vascular integrity since it suppresses sprouting angiogenesis and regulates vascular permeability. Dysfunction of the S1P-S1P receptor signaling system results in various vascular defects, such as exaggerated angiogenesis in developing retina and augmented inflammation due to increased permeability. Endothelial-specific deletion of S1P1 receptor in mice fed high-fat diet leads to increased formation of atherosclerotic lesions. This review highlights the importance of the S1P-S1P receptor signaling system in inflammatory processes. We also describe our recent findings regarding a specific S1P chaperone, apolipoprotein M, that anchors to high-density lipoprotein and contributes to shaping the endothelial-protective and anti-inflammatory properties of high-density lipoprotein. © The Japanese Society for Immunology. 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  G-protein-coupled receptor; lipid mediator; lysophospholipid; sphingolipid

Mesh:

Substances:

Year:  2019        PMID: 31049553      PMCID: PMC6939830          DOI: 10.1093/intimm/dxz037

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  74 in total

1.  The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

Authors:  Daniel J Rader; Alan R Tall
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

Review 2.  Sphingosine 1-phosphate in coagulation and inflammation.

Authors:  Hideru Obinata; Timothy Hla
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

3.  Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy.

Authors:  Petra Keul; Amin Polzin; Klaus Kaiser; Markus Gräler; Lisa Dannenberg; Günter Daum; Gerd Heusch; Bodo Levkau
Journal:  FASEB J       Date:  2018-08-21       Impact factor: 5.191

4.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.

Authors:  K Chiba; Y Yanagawa; Y Masubuchi; H Kataoka; T Kawaguchi; M Ohtsuki; Y Hoshino
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

5.  Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease.

Authors:  Katherine J E Sattler; Sehriban Elbasan; Petra Keul; Miriam Elter-Schulz; Constantin Bode; Markus H Gräler; Martina Bröcker-Preuss; Thomas Budde; Raimund Erbel; Gerd Heusch; Bodo Levkau
Journal:  Basic Res Cardiol       Date:  2010-07-21       Impact factor: 17.165

Review 6.  Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.

Authors:  John Camm; Timothy Hla; Rajesh Bakshi; Volker Brinkmann
Journal:  Am Heart J       Date:  2014-07-11       Impact factor: 4.749

7.  The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway.

Authors:  Kanae Nakahara; Aya Ohkuni; Takuya Kitamura; Kensuke Abe; Tatsuro Naganuma; Yusuke Ohno; Raphael A Zoeller; Akio Kihara
Journal:  Mol Cell       Date:  2012-05-25       Impact factor: 17.970

8.  Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice.

Authors:  Eric Camerer; Jean B Regard; Ivo Cornelissen; Yoga Srinivasan; Daniel N Duong; Daniel Palmer; Trung H Pham; Jinny S Wong; Rajita Pappu; Shaun R Coughlin
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics.

Authors:  Shobha Thangada; Kamal M Khanna; Victoria A Blaho; Myat Lin Oo; Dong-Soon Im; Caiying Guo; Leo Lefrancois; Timothy Hla
Journal:  J Exp Med       Date:  2010-06-28       Impact factor: 14.307

10.  Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite.

Authors:  T Fujita; K Inoue; S Yamamoto; T Ikumoto; S Sasaki; R Toyama; K Chiba; Y Hoshino; T Okumoto
Journal:  J Antibiot (Tokyo)       Date:  1994-02       Impact factor: 2.649

View more
  59 in total

Review 1.  Malaria link of hypertension: a hidden syndicate of angiotensin II, bradykinin and sphingosine 1-phosphate.

Authors:  Gunanidhi Dhangadamajhi; Shailja Singh
Journal:  Hum Cell       Date:  2021-03-08       Impact factor: 4.174

Review 2.  Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.

Authors:  Jie Wang; Idan Goren; Bo Yang; Sinan Lin; Jiannan Li; Michael Elias; Claudio Fiocchi; Florian Rieder
Journal:  Aliment Pharmacol Ther       Date:  2021-12-21       Impact factor: 8.171

3.  PLTP deficiency-mediated atherosclerosis regression could be related to sphinogosine-1-phosphate reduction.

Authors:  Jiao Zheng; Ke Zhang; Zhiqiang Li; Tilla S Worgall; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2022-07-15       Impact factor: 6.847

4.  Integration of metabolomics and transcriptomics reveals convergent pathways driving radiation-induced salivary gland dysfunction.

Authors:  Lauren Meeks; Diogo De Oliveira Pessoa; Jessica A Martinez; Kirsten H Limesand; Megha Padi
Journal:  Physiol Genomics       Date:  2021-02-01       Impact factor: 3.107

5.  Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors.

Authors:  Molly Congdon; Russell G Fritzemeier; Yugesh Kharel; Anne M Brown; Vlad Serbulea; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  Eur J Med Chem       Date:  2020-12-29       Impact factor: 6.514

Review 6.  An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.

Authors:  Marzia Fronza; Lorena Lorefice; Jessica Frau; Eleonora Cocco
Journal:  Drug Des Devel Ther       Date:  2021-05-11       Impact factor: 4.162

Review 7.  Ceramides and Sphingosino-1-Phosphate in Obesity.

Authors:  Ilona Juchnicka; Mariusz Kuźmicki; Jacek Szamatowicz
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-13       Impact factor: 5.555

Review 8.  The Anti-Infectious Role of Sphingosine in Microbial Diseases.

Authors:  Yuqing Wu; Yongjie Liu; Erich Gulbins; Heike Grassmé
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

9.  Sphingosine-1-phosphate: The missing link between NOD1/2 and ER stress.

Authors:  Yan Lu; Dante Neculai
Journal:  EMBO J       Date:  2021-06-16       Impact factor: 14.012

10.  Increased Sphingosine-1-Phosphate Serum Concentrations in Subjects with Periodontitis: A Matter of Inflammation.

Authors:  Eileen Moritz; Gabriele Jedlitschky; Bernhard H Rauch; Birte Holtfreter; Josefine Negnal; Mladen V Tzvetkov; Günter Daum; Marcus Dörr; Stephan B Felix; Henry Völzke; Matthias Nauck; Edzard Schwedhelm; Peter Meisel; Thomas Kocher
Journal:  J Inflamm Res       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.